
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Digital Tool Helps More Adults Get Screened for Lung Cancer
2
ICER Analysis Finds Net Prices of New Drugs Rose 51% Over Three Years
3
Dermatologist James Song Talks about Managing Psoriasis with IL-23 Inhibitors | Fall Clinical 2025
4
Data From Two Rebyota Trials Show Quality of Life Improvements | IDWeek 2025
5




















































